Podcasts about jlabs

Transforming Chronic Pain Treatment with a Lean, Data-focused Development StrategyBased in Washington, DC, AlgometRx has developed a technology platform that will let clinicians perform objective pain assessments to improve treatments for chronic pain.In Episode 37 of the MedTech Speed to Data Podcast, Key Tech's Andy Rogers and AlgometRx Chief Operating Officer Kevin Jackson discuss how collecting the right data sped the Nociometer platform's development.Need to knowPain diagnosis is challenging — Patients self-report their experience, which is inherently subjective and variable.Pain treatment involves trial and error — Finding the right treatment plan often requires a months-long iterative process.Risks of inappropriate drug treatments increase — Poor understanding of pain's causes leads to the over-prescription of the wrong drugs, a contributing factor to the opiate crisis.The nitty-grittyAlgometRx's technology platform emerged from research by the company's founder, Dr. Julia Finkel at Children's National Hospital. A pediatric anesthesiologist, Dr. Finkel must assess pain in children who lack the words to describe their experiences.“She wanted something that she could use in clinic to help better understand patients' pain,” Jackson explains. “Something that's simple enough that anyone could use in a variety of settings.”The Nociometer platform selectively activates nerve fibers and evaluates the patient's physical response — without causing additional pain.“We're able to identify the physiologic underpinnings of that pain experience, and that allows clinicians to better understand what's happening.”An objective assessment of the patient's pain lets the clinician make faster, better-informed decisions, but the real value will come from monitoring treatments. Rather than waiting three months to see if a treatment works, patients can return to the clinic a week later for a follow-up measurement. “That gives the clinician different information they wouldn't have had, Jackson says. “We can get right to the root of it, and you avoid six, seven, eight visits.”Data that made the difference:AlgometRx discussed this first-of-its-kind technology with the FDA before developing its proof-of-concept prototype. “We had this novel concept of a pain biomarker and device, so we wanted to know how we would even bring a device like this [to market].” FDA feedback informed a development strategy focused on gathering data from specific populations.AlgometRx leveraged partnerships to support this focused strategy. Working with Johns Hopkins researchers under an NIH Sprint for Women's Health grant, AlgometRx is developing pain response data sets for patients with systemic lupus and carpal tunnel syndrome. The startup is also a member of JLABS, Johnson & Johnson Innovation's life sciences incubator, where they get valuable insight into the Nociometer platform's potential role in pharmaceutical research.Running a lean operation lets AlgometRx prioritize data. Jackson is the startup's only full-time paid employee. Dr. Finkel, AlgometRx's board, and a network of consultants and contractors bring their expertise as needed. “We don't have a robust employee base, but we have a robust team,” Jackson says. “We've run this lean approach where we only bring in people as needed. Obviously, our investors love that idea because it's spending money on device development and data generation.”

Timestamps: 5:22 - From the UK to Switzerland 11:29 - The dark genome and chronic diseases 17:35 - HTX001 and heart failure 26:44 - Sticking to grants at first 34:32 - Managing two separate teams This episode was sponsored by smzh, your independent go-to partner in all matters relating to finance. About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at Imperial College London, University College London and CHUV Lausanne University Hospital before starting HAYA in 2019, together with his co-founder Daniel Blessing. Early on in his academic career Samir studied the so-called “dark genome” (also known as the “regulatory genome”), which at the time of discovery (2001) was considered “junk DNA”, i.e. the 98% of our DNA that apparently did not make or in any way affect our genes. More recent scientific research has discovered that this regulatory genome is key to understanding how our genes interact with our environment, and can therefore be useful in targeting environment-caused diseases like heart failure and cancer. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. The added benefit of their drugs is that by targeting the “dark” 98%, instead of the 2%, they result in zero side effects: conventional drugs help patients treat their diseases but they also produce secondary unwanted effects because the proteins that they are targeting (in our 2%) are also responsible for other functions — this same issue does not exist when it comes to drugs which interact with the dark genome. HAYA Therapeutics is headquartered at the life sciences park Biopôle, in Lausanne, with additional laboratory facilities at JLABS, San Diego. They have raised a total of $25M in funding backed by a strong consortium of investors, including Broadview Ventures, Apollo Health Ventures, 4SeeVentures, BioInnovator, Bernina Bioinvest, Humboldt and Schroder Adveq. This cover portrait was edited by www.smartportrait.io Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS' national and international footprint, and the significant partnerships with organizations like Children's National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

Back in June, MTPConnect led the Australian delegation at BIO 2024 in San Diego organising a range of activities to showcase Australia's innovative life sciences sector to the international biotech industry. With a powerful #TeamAustralia focus and a 500-strong delegation from Australia, BIO2024 was the biggest and best ever! In this BIO Bites episode, hosts Caroline Duell and Stuart Dignam catch up with Australian and global companies, entrepreneurs and researchers doing business at BIO and find out what all the buzz is about at the world's largest biotech partnering event. We take a tour around San Diego's ecosystem catching up with Rachel Rath from the Blue Knight Initiative at J&J Innovation's JLABS who are supporting early-stage companies, and Dena Marrinucci from US startup Truvian Health who are working with Planet Innovation on a portable blood testing platform. At the Australian Pavilion we chat with University of Adelaide 's Prof Mark Hutchinson on defence and the SABRE Alliance and find out how statistics and AI are adding value to the life sciences sector with Adelaide Data Science Centre's Dr Melissa Humphries. Topelia Australia's David Fox talks about their antiviral therapeutic targeting coronavirus infections, Bridgewest Ventures' Saum Vahdat explains their investment in drug manufacturing in Australia and Attentive Science Australia's Holly Stefl discusses their recent expansion into the clinical trial ecosystem in Australia. 

At the recent Consumer Electronics Show (CES) in Las Vegas, companies from around the world showcased their latest technologies. Dave Kemp hosts Andrew Bellavia to discuss his firsthand experience at CES, with a focus on innovations in hearing and hearable devices. Andy sheds light on the overarching technological advancements that are shaping the future of hearing devices. During his time at CES, Andy had insightful discussions with various companies. He spoke with EssilorLuxottica about their groundbreaking hearing aid glasses and visited Absolute Audio Labs to explore their latest developments and partnership with Renesas. Additionally, Andy engaged in discussions with the teams from Knowles and AVAtronics, as well as JLabs' plans for entering the over-the-counter (OTC) market in 2024. Dave and Andy analyze the implications of these new developments and discuss the latest trends in the hearing health and audio industries. They highlight key takeaways from CES, offering valuable insights into the future of audio technology and its impact on hearing health. Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn and Twitter. - https://twitter.com/WeekinHearing - https://www.linkedin.com/company/this-week-in-hearing - https://hearinghealthmatters.org/thisweek/

Hey

The burden of cancer, mental illness and other diseases is growing and according to a report by Statista, residents aged 65 years and above make up 16.6 percent of the total resident population in Singapore. This makes early health intervention critical in addressing these national healthcare issues,  So how is Johnson & Johnson Innovation – JLABS recent collaboration with EDB enabling and empowering emerging healthcare companies with the knowledge, experience and venture connections across a spectrum of pharmaceutical and medical technology sectors?  Melinda Richter, Global Head, Johnson & Johnson Innovation – JLABS shares more.   See omnystudio.com/listener for privacy information.

I've always said that my journey to TEDx was more impactful than actually giving the talk itself; it was a journey in clarity and effective communication. I had to get across big ideas in only 12 minutes.  Today I'm joined by John Bates, a TED talk expert who explores the neurobiological principles of communication. Together, we unravel the secrets behind creating engaging, emotionally resonant speeches, and offer practical advice on connecting with your audience and embracing the fear that often accompanies public speaking. This conversation is full of insights for self-employed business owners looking to master the art of impactful communication and storytelling.   John Bates is a TED and TEDx speaker, Leadership Communications Executive Coach, Author, and Keynote Speaker with a deep focus on communication rooted in neurobiology. He is renowned for his coaching excellence in the TED format. His clients, including notable organizations like Johnson & Johnson's JLABS, NASA, US Navy Special Operations, GE Aviation, and Boston Scientific, highly recommend him as a premier leadership communications coach. John's expertise lies in alleviating speaking anxiety, fostering strong leadership presence, and cultivating trust, loyalty, and connection through effective communication. His science-based approach benefits both logical, introverted individuals, and ambitious thought leaders, enabling them to craft influential speeches. John also offers top-tier pitch coaching, with affiliations in prestigious programs like Johnson & Johnson Innovations JLABS and Cisco Global Problem Solver Challenge, empowering entrepreneurs to succeed in pitch competitions, secure VC funding, and obtain grants.   And be sure to subscribe to The Self-Employed Life in Apple Podcasts or follow us on Spotify or wherever you listen to podcasts so you don't miss an episode.   Everything you need can all be found at jeffreyshaw.com.   John Bates, thank you so much for being here! Remember, you might be in business FOR yourself but you are not in business BY yourself. Be your best self. Be proud and keep changing the world. Guest Contact – JohnBates.com  Your Amazing Itty Bitty Guide to Being TED-Worthy: 15 Essential Secrets of Successful Speaking Based in Human Neurobiology by John Bates Register for John's Free Weekly Mini-trainings John Bates on LinkedIn (in/johnbates) John Bates on Facebook (@ExecutiveSpeakingSuccess) John Bates on Twitter/X (@johnbates) John Bates on YouTube (@ExecSpeakingSuccess) John Bates on Vimeo (@johnkbates) Contact Jeffrey – SelfEmployedNewsletter.com Website Books Watch my TEDx LincolnSquare video and please share!   Valuable complimentary resources to help you –   ·       The Self-Employed Business Institute- You know you're really good at what you do. You're talented, you have a skill set. The problem is you're probably in a field where there is no business education. This is common amongst self-employed people! And, there's no business education out there for us! You also know that being self-employed is unique and you need better strategies, coaching, support, and accountability. The Self-Employed Business Institute, a five-month online education is exactly what you need. Check it out! ·       Take The Self-Employed Assessment! Ever feel like you're all over the place? Or frustrated it seems like you have everything you need for your business success but it's somehow not coming together? Take this short quiz to discover the biggest hidden gap that's keeping you from having a thriving Self-Employed Ecosystem. You'll find out what part of your business needs attention and you'll also get a few laser-focused insights to help you start closing that gap. ·       Have Your Website Brand Message Reviewed! Is your website speaking the right LINGO of your ideal customers? Having reviewed hundreds of websites, I can tell you 98% of websites are not. Fill out the simple LINGO Review application and I'll take a look at your website. I'll email you a few suggestions to improve your brand message to attract more of your ideal customers. Fill out the application today and let's get your business speaking the right LINGO! Host Jeffrey Shaw is a Small Business Consultant, Brand Management Consultant, Business Coach for Entrepreneurs, Keynote Speaker, TEDx Speaker and author of LINGO and The Self Employed Life (May 2021). Supporting self-employed business owners with business and personal development strategies they need to create sustainable success.

Melinda Richter and Stacy Feld of Johnson & Johnson Innovation discuss healthcare innovation and technology, including J&J's involvement in SXSW, the potential for Austin as a major biohub, and both the challenges and opportunities the sector faces.Episode HighlightsJ&J's sponsorship of the Health and MedTech track at SXSW signifies a shift for both J&J and the overall festival, showing its growing prominence.JLABS is an example of J&J's approach between internal and external collaboration to help early-stage innovators by giving them access to resources and expertise they need to bring their solutions to market.Consumerization of healthcare is a trend that can make healthcare more affordable and accessible but finding the right business model can be difficult.Austin is a potential hub for healthcare innovation, and discussions about healthcare innovations and business models at SXSW could lead to a more efficient and effective healthcare system.J&J recognizes the importance of leveraging data and insights to become more effective and efficient in providing care and solutions.The future of telehealth is likely to include continued growth and innovation, as healthcare providers and patients become more comfortable with remote care and technology continues to improve.What's next for Austin?Stacy Feld: "Continuing to unlock the value of the rich academic and clinical institutions, not just with UT and Austin, but across the Texas Triangle and to find the synergies and pair our disease area expertise and the resources that we have with entrepreneurs and with academics." Melinda Richter: "What's next for Austin is to become that next big player for health tech, solving equity and access issues, changing patient care and lives, and leading the charge. All of those things together combined with such a diverse population, people coming from all over the world."What's next for J&J in Austin?Stacy Feld: "Building new early relationships with entrepreneurs, launching new companies out of academia, and continuing to invest in building long-term relationships." Melinda Richter: "There's going to be an amazing hub at SXSW with lots of J&J folks from around the company in different disciplines. And so we really want to have these conversations with everybody. So please reach out, come see us, and certainly, we want to continue to grow that conversation over time."Episode LinksTop 10 Tips for Standing Out at Pitch CompetitionsMelinda Richter: LinkedIn, TwitterStacy Feld: LinkedIn, TwitterJ&J Innovation: Website, TwitterJLABS: Website, Twitter Austin Next Links: Website, X/Twitter, YouTube, LinkedIn

“Really understand communication and influence so you can be the best contributor to teams that you can be.”In this episode, we speak about the importance of having great communication skills as a leader. We go beyond public speaking - more importantly, understanding the influence and impact that this skill brings.  To get you excited and bring out your ability to speak effectively, I've invited one of the most prolific TED format coaches in the world to help me deliver this topic. Someone who knows the power that mastering the TED format can bring to anyone - not just at work but also in life. PROMOS**Free for Leaders Lab Listeners: Starting January 1st, Tommy Rosen will be leading a live, one-hour morning spiritual practice every day at 6:00 am PT, for the entire month of January. Sadhana is a morning spiritual practice aimed at helping you reconnect to your true self so that you can set your day up for success. To register and for more info: r20.com/WakeUp2023ABOUT OUR GUESTAfter totally blowing his first time on the TED Stage, John Bates set his focus and is now a global Leadership Communications Expert, Executive Coach, Author, Pitch Coach and Keynote Speaker. Leaders from organizations like Johnson & Johnson's JLABS, NASA (including the Astronauts), US Navy Special Operations, Boston Scientific, NORAD, and more, recommend him to their colleagues as the best leadership communications coach working today. He designs all of his programs using principles derived from neurobiology, so your COMMUNICATION is as mighty as YOUR IDEAS.John Bates‘ mission is to bring out what is awesome inside of forward-thinking, growth-mindset leaders, so they can have the impact they want to have on the world. He supports leaders who are slightly nervous on stage in becoming totally TED-Worthy, confident, relaxed,  and influential. He also supports excellent communicators who want to take the next level for themselves. Find his bestselling book at Amazon: Your Amazing Itty Bitty Guide to Being TED-Worthy: 15 Essential Secrets of Successful Speaking Based in Human Neurobiology. You can learn more about John and his work here:https://executivespeakingsuccess.com/subscribe/https://johnbates.com/https://www.linkedin.com/in/johnbates/ABOUT OUR HOSTKen Eslick is an Entrepreneur, Author, Podcaster, Tony Robbins Trainer, Life Coach, Husband of 35+ Years, and Grandfather. Ken currently spends his time as the President & Founder of The Leaders Lab where he and his team focus on Senior Leadership Acquisition. They get founders the next level C-Suite Leaders they need to go from being an Inc. Magazine 5000 fastest growing company to $100,000,000 + in revenue. You can learn more about Ken and his team at:theleaderslab.coListen to more episodes on Mission Matters:https://missionmatters.com/author/ken-eslick/

MTPConnect hits The MedTech Conference in Boston, USA, leading a delegation of 18 Australian companies to showcase Australia's outstanding innovative medical technologies and capabilities to the world's largest medtech market. With the creation of the unmissable Australian Pavilion exhibit and a top-level visit program of keynotes and networking events, the mission was supported by Austrade and state partners Global Victoria, Invest & Trade Western Australia, NSW Health, Trade and Investment Queensland and the Government of South Australia.In this first episode of our two-part special, MTPConnect CEO Stuart Dignam chats to Rachel Rath, Director of the BARDA Alliance for Johnson & Johnson Innovation after Team Australia toured the JLABS life science and healthcare incubator, the newest in J&Js worldwide stable of facilities. He also catches up with Australian cardiologist, Professor Ian Meredith, Executive Vice President and Global Chief Medical Officer from Boston Scientific, Caroline McCaffrey, Director of Investment & Trade at Global Vic and some Team Australia delegates including, iishield's Dr Jeremy Kwarcinski, Hydrix's Peter Lewis, Design and Industry's Adam Donath, Cortical Dynamics' Ashley Zimpel and Jay-Nik's Clare Brown.

Go Big or Go Home: John Flavin talks Texas-style life sciences with innovation leaders https://www.linkedin.com/in/thomas-luby-aa0b743/ (Tom Luby) and https://www.linkedin.com/in/smhein/ (Sarah Hein) from https://www.tmc.edu/innovation/ (Texas Medical Center Innovation) in e.018. New developments in Houston are setting the stage for accelerated growth in the start-up ecosystem. Investments being made by member institutions such as MD Anderson, Baylor, Texas A&M, Texas, Rice and others into innovation platforms and top-tier applied researchers means: more commercialization of new drugs and devices is on the horizon. TMC is building the infrastructure and community to create the conditions to allow for rapid scaling of the ecosystem. Tom Luby Ph.D. is the Director of Texas Medical Center (TMC) Innovation.  In this role, he oversees all of the innovation efforts of TMC focused on research, education, and commercialization of novel healthcare solutions.  Prior to this, he was the head of JLABS @ TMC in Houston, Texas.  Tom started at https://jnjinnovation.com/home (Johnson & Johnson Innovation) as a New Ventures Lead at the Johnson & Johnson Innovation Center in Boston. In that role, he was instrumental in fostering many deals for the Boston office, which included the expansion of JLABS to JLABS @ Toronto.  Prior to J&J, Tom spent 14 years in various R&D and business development positions, most recently as Sr. Director, Research Ventures at Shire. Nine of those years were spent working in R&D and operational roles across three start-up biotech companies in the Boston area. Tom received a Bachelor of Science in Biology from State University of New York, and a Ph.D. in Immunology from the Sackler School of Biomedical Sciences at Tufts University. Sarah Hein, PhD, is an Entrepreneur in Residence for the https://www.tmc.edu/innovation/accelerator-cancer/ (Texas Medical Center's Cancer Therapeutics Accelerator). Previously, Sarah was cofounder and VP of Operations at https://www.linkedin.com/company/courier-therapeutics/ (Courier Therapeutics), where she helped develop a novel immune-targeted cancer immunotherapy. She was also Director of Research at https://www.linkedin.com/company/resonant-therapeutics/ (Resonant Therapeutics), an antibody therapeutics platform technology company. She began at https://www.linkedin.com/company/mercury-fund/ (Mercury Fund )as a Venture Fellow directly after graduating with her PhD from Baylor College of Medicine. Sarah earned her Bachelor's and Master's of Science from the University of Wyoming.

This episode features Dr. Kenneth Bahk, Co-founder and Managing Partner at Kaleidoscope Health Ventures, & Dr. Katherine Merton, Head of Johnson & Johnson Innovation, JLABS @ NYC. Here, they discuss Chicago ARC, a collaborative innovation model to drive health equity and healthcare transformation.

In this episode, Gregory Montalbano speaks with Dr. Tom Luby who is the Director of Innovation at Texas Medical Center also known as TMC Innovation. In this role, Tom oversees all of the innovation efforts of TMC focused on research, education, and commercialization of novel healthcare solutions. Prior to Tom's role at TMC, he was the head of JLABS at TMC in Houston, Texas. In this episode, a deep-dive will be taken into the inner-workings of the Houston TMC Innovation and JLABS ecosystem. Greg and Tom discuss the methods of mentoring and support offered to the entrepreneurial groups spanning medical, scientific, and biotechnology applications. Tom also outlines the various TMC & JLABS corporate, university, industry as well as venture partner networks that support their members. Greg and Tom's discussion also includes what TMC Innovation looks for in a startup and how they can apply to TMC's programs.

We have to write our relationship with our businesses, and not let the businesses take over our lives, but as successful as we can become as entrepreneurs, success doesn't automatically carry over into our personal lives. Today's guest has a very powerful life experience he would like to share and his story is featured in Dr. Sabrina's newly-released The 4 Week Vacation™ book! Listen in as John Bates walks us through some of his most challenging professional and personal moments and the lessons that came out of it. John Bates‘ mission is to bring out what is awesome inside you, so it can live in the world and make a real difference. He designs his programs using principles derived from neurobiology so your communication is as mighty as your ideas. John is an in-demand executive coach. He is also one of the most prolific TED-format coaches in the world. Executives from organizations like Johnson & Johnson's JLABS, NASA (including the Astronauts), US Navy Special Operations, Boston Scientific, and more recommend him to their colleagues as the best leadership communication coach working today. He knows the power creating a TED-like talk can bring to anyone, in business, and in life. John's training is derived from human evolutionary biology and human neurophysiology, so you learn not only what works, but also WHY it works. That gives you principles you can apply to your unique style, which will allow you to achieve ever-increasing success and the ability to play and create in the areas of communication and leadership. John has trained thousands of TED/TEDx/TED-format speakers all over the world. He also works with C-level executives at top companies to make their communications "TED-Worthy." His ongoing program, Live Like a Leader, supports executives, entrepreneurs, influencers, and leaders in being fully integrated, influential leaders. And his podcast, SpeakLikeaLeader.show, inspires people from all over the world. Profit by Design is a Tap the Potential Production in collaboration with Small Business Consulting Group. Show Highlights: John relates a personal, life-changing experience. Dr. Sabrina shares the importance of completing the stress cycle. What a “mid-week weekend” can do for you! Take four weeks away from my business, seriously? (Yes, seriously.) If you're a “one-man band”, you will always play small. Be clear on the idea that you want to bring to the world. John and Dr. Sabrina discuss public speaking and suggest tips for effective communication. Are you ready to Speak Like a Leader? Check out the courses that John offers! If you're ready to take your life back from your business, purchase your copy of The 4 Week Vacation™  (plus you get a bonus!) and join us in the Entrepreneurs Take Your Life Back! Community Facebook group. Connect with John! Find him on his Website, LinkedIn, Facebook, Instagram, or Twitter. Links and Resources: New! Now Available!! The 4 Week Vacation™ book with bonuses! Download Dr. Sabrina's Introductory Training: How to Make Your Time Worth $10,000 an Hour Join Dr. Sabrina in our Entrepreneurs Take Your Life Back! Community  

Ana Moreno holds a PhD in Bioengineering from UCSD and is the founder and CEO of Navega Therapeutics. Ana and I had a few hard kombuchas from June Shine while we discussed the source of her entreprenurial spirit, Navega's goal of giing people an alternative pain management solution, the mythical place known as JLabs and more.

Michael W. Nestor, PhD, Scientific Engagement Lead JLABS @ Washington, DC - Johnson & Johnson Innovation, discusses establishing a Johnson and Johnson's JLabs in the area and his background in neuroscience. Including stem cell research. https://jlabs.jnjinnovation.com/locations/jlabs-washington-dc

15000% - tyle urósł SpyroSoft w ciągu 3lat. To dało im 5te miejsce pośród najszybciej rosnących firm w Europie wg. rankingu Financial Times FT1000. Pośród firm IT pierwsze. W rankingu znalazło się jedynie 31 firm z Polski w tym J-LABS.O tym jak to się robi, żeby odnieść tak spektakularny sukces opowiada Konrad Weiske. Założyciel i współwłaściciel SpryroSoft.Główne zagadnienia odcinka:

Jak myśli i działa Piotr Bucki? Jak zbudować firmę taką jak J-LABS? Krzysztof Wojewodzić z Escola Mobile pyta, Piotr Bucki odpowiada. Ten odcinek jest zapisem live Escola Mobile.Rozmowa jest o: • Dlaczego w swoim podcastcie daje dokładne wskazówki jak robić biznes? • Dlaczego sukces w biznesie jest naturalną konsekwencją...? No właśnie czego? • Jak ma się sport do sukcesu w biznesie? • Jak to było na początku? • Czy od początku j-labs miał być dużą skalowalna firma? • Czy zaprojektowałem firmę i tak to potem zrobiliśmy? • Co jest łatwe w skalowaniu? • Co jest trudne w skalowaniu firmy? • Prywatne motywacje w budowaniu i rozwijaniu firmy. • Ile godzin pracuje teraz a ile pracowałem na początku? • Jakie są moje największe porażki? • Na ile ważne są emocje w biznesie? • Na ile ważna jest intuicja? • Jaki jest mój następny cel? • Jak zbudować firmę taką jak j-labs? • Jak to jest z kapitałem na start - jest potrzebny czy nie? • Jak zbudować skuteczny system sprzedażowy, który działa bez założyciela? • Rekrutacja, czyli jak dobierać sobie ludzi do zespołu.Czyżby to była esencja pytań biznesowych jakie można zadać?Escola Mobile:https://link.chtbl.com/aiMobile Krzysztof Wojewodzichttps://www.linkedin.com/in/krzysztofwojewodzic/Escola S.A.https://escola.pl/Link do odcinka, transkryptu i wszystkich niezbędnych informacji: • www.piotrbucki.pl/056Newsletter • www.piotrbucki.pl/newsletter

Piotr Bucki J-LABS w Escola Moblie To ponad 100 minut konkretnego, biznesowego miąższu.    Biznesmen, współwłaściciel firmy IT, zatrudniającej 350 osób. Podcaster, prowadzący audycję Biznes w IT, gdzie dzieli się wiedzą o tym jak buduje swoją firmę. W rozmowie poruszymy takie tematy jak skalowanie firmy, co w tym jest najtrudniejszego. Czy już na początku planem Piotra było stworzenie dużej firmy? To rozmowa o prowadzeniu biznesu, od prywatnych motywacji przez zarządzanie, rekrutację i rozwijanie przedsiębiorstwa.Jakie są relacje marki osobistej foundera i marki firmy. Zostań z nami do końca. Ta rozmowa to sam biznesowy miąższ. Zapraszamy do wysłuchania rozmowy z Piotrem Buckim z J-Labs.     Piotr Bucki: https://www.linkedin.com/in/piotr-bucki/   Kontakty do Escola Mobile: Krzysztof Wojewodzic: http://bit.ly/KWojewodzic Mail: krzysztof@escolasoft.com Jędrzej: http://bit.ly/JPaulus Mail: jedrzej@escolasoft.com Strona: https://escola.pl/   Muzyka: Kevin MacLeod Werq Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License/mix by Jedrzej Paulushttps://creativecommons.org/licenses/by/4.0/   Oceń nasz podcast na itunes: https://bit.ly/EscolaMobileIT

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.Follow Melinda on Twitter.

Sally Allain, MSc., MBA , Head, JLABS @ Washington, DC, joins Rich Bendis on BioTalk to discuss her career, the decision to open a BioHealth Capital Region location, and their new BLUE KNIGHT™ collaboration.

Ponad 10 lat doświadczeń i wiele godzin przemyśleń zebranych w jednym odcinku. Odcinku na temat najważniejszych aspektów związanych z skutecznym skalowaniem firmy. Tematy poruszane w odcinku: • Czy model biznesowy jest skalowalny. • 3 stadia rozwoju skalowalnej firmy. • Ludzie. • Misja, wizja, strategia… i konsekwencja. • Sprzedaż. • Zasady i procesy. • Delegowanie. • Finanse.W ramach dodatku studium przypadku j-labs – firmy IT zbudowanej organicznie od zera do 350 pracowników.Link do odcinka, transkryptu i wszystkich niezbędnych informacji: • www.piotrbucki.pl/053Newsletter • www.piotrbucki.pl/newsletter

Ponad 10 lat doświadczeń i wiele godzin przemyśleń zebranych w jednym odcinku. Odcinku na temat najważniejszych aspektów związanych z skutecznym skalowaniem firmy. Tematy poruszane w odcinku: • Czy model biznesowy jest skalowalny. • 3 stadia rozwoju skalowalnej firmy. • Ludzie. • Misja, wizja, strategia… i konsekwencja. • Sprzedaż. • Zasady i procesy. • Delegowanie. • Finanse.W ramach dodatku studium przypadku j-labs – firmy IT zbudowanej organicznie od zera do 350 pracowników.Link do odcinka, transkryptu i wszystkich niezbędnych informacji: • www.piotrbucki.pl/053Newsletter • www.piotrbucki.pl/newsletter

For more on JLABS, go to https://jlabs.jnjinnovation.com/JLABSNavigator#/As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA). 

In Episode 3 of this special series on self-care and strategy for entrepreneurs, Dr. Sabrina, The Business Psychologist™, addresses what we are going through as business leaders and entrepreneurs and reminds us of why self-care is so important during this time. Today’s guest, John Bates, joins her to discuss leadership in a virtual age. We’ve all been thrown into virtual leadership recently due to the COVID-19 event, and this presents its own unique challenges, such as how we are going to connect emotionally with the people whom we are trying to lead. John’s “why” is to unleash what is great in all of us so that it can live in the world. John lives that “why”, and he has a lot to share. Stay tuned for this insightful conversation! John Bates has spoken, hosted, and coached for over 35 different worldwide TED and TEDx events. He’s been privileged to get to know some of the top leaders in the world, the NASA astronauts, the leaders at Johnson & Johnson, JLABS, Accenture, Boston Scientific, Coca-Cola, and many others, including many Tap the Potential clients. He works with people on a very deep, personal level. The amount of vulnerability, openness, self-reflection, and honesty that a well-done TED-format talk requires is second to none. The insights into leadership, success, and fulfillment in life that John has gained from his years of experience with this allow him to share some of the biggest, most powerful secrets of truly successful leadership that exists.  Profit by Design is a Tap the Potential Production in collaboration with Small Business Consulting Group. Show Highlights: John shares his successful, earlier days of entrepreneurship and his deadly struggle with an autoimmune disease, which seemed to be triggered by stress and a lack of sleep. To get out of the hole he found himself in, he had to really learn how to take care of himself. There is no greater time than the present to be paying more attention to self-care so that we are able to share ourselves with others. Assess your entrepreneurial burnout for FREE HERE. You will get feedback that shows your current risk for burnout and if you have more than 3 symptoms, you are at high risk and will need to look at self-care measures to put in place. Dr. Sabrina details her self-care strategies: Sleep - at least 8 hours per night Only check social media and major news sources once per day, preferably mid-day Exercise Meditation (Dr. Sabrina enjoys the Calm App!) Journaling John expounds on Dr. Sabrina’s self-care strategies and offers his own tips: Self-care is for men, too! It’s necessary to stay in the fight. Box breathing  John also loves the Calm App! Others to consider are the Headspace App and the Waking Up App. Dr. Sabrina shares another level beyond worry and fear that we need to be talking about and that is grief and loss, and how these are affecting our children. This is an opportunity to look for new ways of working, new ways to be productive, and new ways to engage family and life. We can take this time as an opportunity to think about what we have to be grateful for and the good things that are coming out of this time. John addresses how important your tele-presence is to your leadership. Psychologically, the more senses we can engage, the better. John and Dr. Sabrina offer tips for successful video meetings. Ways to encourage and motivate your team to further your team goals. John teaches a course to help build your skills as a virtual leader.  The Q-Storming protocol is a useful tool that bypasses crisis-oriented tunnel vision. Current and past clients can request a FREE laser-coaching session. If you’ve never been a client, check out a 45-minute Q-Storming strategy session here: https://www.tapthepotential.com/strategy. It is a $250 investment. An encouraging rally-cry: “Lead with love. Shine bright. Be a gift.” Links and Resources: Taking care of yourself is important now more than ever. Are you ready to take your life back from your business?  The FIRST STEP is taking our Assessment at: https://www.tapthepotential.com/assessment NEXT, meet with our Success Team Lead to debrief your results. THEN, join our Better Business, Better Life™ program! Tap The Potential Strategy Session for Entrepreneurs Impacted by COVID-19 https://www.tapthepotential.com/strategy Get the Book!! How to Hire the Best - Contractors Editionwww.TapThePotential.com/book How to Hire the Best Toolkit www.TapThePotential.com/Toolkit Get Your 2020 Action Planner Now! The Pumpkin Plan Action Planner 2020 https://www.tapthepotential.com/planner Dr. Sabrina’s WEBSITE Dr. Sabrina’s PODCAST - PLEASE RATE & REVIEW! Profit by Design, a Tap the Potential production in collaboration with Small Business Consulting Group For Resources & Tools from Sponsors - https://www.profitbydesignpodcast.com Subscribe & Share Podcasts! - https://www.profitbydesignpodcast.com/podcasts/ Facebook Group: https://www.facebook.com/groups/ProfitByDesign/ The Q-Storming protocol is a useful tool that bypasses crisis-oriented tunnel vision. Current and past clients can request a FREE laser-coaching session. If you’ve never been a client, check out a 45-minute Q-Storming strategy session here: https://www.tapthepotential.com/strategy. It is a $250 investment. Calm App Headspace App Waking Up App Are You Leading with Love or Know Another Entrepreneur Who Is Being a Gift from Their Gifts During This Time? Please use hashtags #leadwithlove #beagift and we will be re-posting these social media posts! Connect with John! John’s Website John’s Twitter John’s Facebook Speak Like a Leader Bootcamp

J-labs od kuchni – zarządzanie w kryzysie korona wirusa. Czyli co i jak można zrobić, aby ryzyko zmniejszenia zapotrzebowania na usługi informatyczne nie przenosiło się na pracowników. A nawet jakby tak się stało to co można zrobić, aby ich ochronić.Z odcinka można dowiedzieć się: • co można zrobić; • jak zorganizować się w takiej sytuacji; • jak wykorzystać potencjał różnych działów; • co w sytuacji, gdy wykraczamy poza normalna sytuacje przewidzianą w modelu biznesowym; • dlaczego zdywersyfikowana firma jest stabilniejsza i bezpieczniejsza w kryzysie;Link do odcinka, transkryptu i wszystkich niezbędnych linków: • www.piotrbucki.pl/049Newsletter • www.piotrbucki.pl/newsletter

J-labs od kuchni – zarządzanie w kryzysie korona wirusa. Czyli co i jak można zrobić, aby ryzyko zmniejszenia zapotrzebowania na usługi informatyczne nie przenosiło się na pracowników. A nawet jakby tak się stało to co można zrobić, aby ich ochronić.Z odcinka można dowiedzieć się: • co można zrobić; • jak zorganizować się w takiej sytuacji; • jak wykorzystać potencjał różnych działów; • co w sytuacji, gdy wykraczamy poza normalna sytuacje przewidzianą w modelu biznesowym; • dlaczego zdywersyfikowana firma jest stabilniejsza i bezpieczniejsza w kryzysie;Link do odcinka, transkryptu i wszystkich niezbędnych linków: • www.piotrbucki.pl/049Newsletter • www.piotrbucki.pl/newsletter

Wnikliwe spojrzenie na pierwsze lata budowania 300 osobowej firmy IT. Odcinek zawiera ważne wydarzenia wraz z kluczowymi wnioskami z początku budowania j-labs. Obejmuje lata 2010-2013. Czyli okres testowania modelu biznesowego i wstępnego skalowania go. Opisuje przejście od pomysłu do ponad 50 pracowników.Jest to retrospektywne podejście po kilku latach do tego co i jak się wydarzyło z perspektywy osoby zakładającej i zarządzającej j-labs.Fanpage podcastu - like/follow aby wiedzieć więcej. • www.facebook.com/PiotrBuckiBizneswIT • www.linkedin.com/company/biznes-w-itSocial media - zapraszam do znajomych. • www.facebook.com/piotr.bucki.1 • www.linkedin.com/in/piotr-buckiStrona podcastu • www.piotrbucki.pl

Wnikliwe spojrzenie na pierwsze lata budowania 300 osobowej firmy IT. Odcinek zawiera ważne wydarzenia wraz z kluczowymi wnioskami z początku budowania j-labs. Obejmuje lata 2010-2013. Czyli okres testowania modelu biznesowego i wstępnego skalowania go. Opisuje przejście od pomysłu do ponad 50 pracowników.Jest to retrospektywne podejście po kilku latach do tego co i jak się wydarzyło z perspektywy osoby zakładającej i zarządzającej j-labs.Fanpage podcastu - like/follow aby wiedzieć więcej. • www.facebook.com/PiotrBuckiBizneswIT • www.linkedin.com/company/biznes-w-itSocial media - zapraszam do znajomych. • www.facebook.com/piotr.bucki.1 • www.linkedin.com/in/piotr-buckiStrona podcastu • www.piotrbucki.pl

Jak zbudować firmę od zera do 300 pracownikówUruchamiając ten podcast i kanał na youtube zakładałem sobie jedną rzecz - co jakiś czas zaprosić interesująca osobę, z którą będzie można na luzie porozmawiać i jednocześnie wiele się nauczyć.I tak właśnie jest dziś.Moim gościem jest Piotr Bucki. Założyciel J-Labs. Człowiek, który od zera zbudował firmę zatrudniającą 300 pracowników. Gość inspirujący i motywujący. Nie ukrywam, że po zakończeniu nagrania, które zaraz obejrzycie miałem niemal gęsią skórkę i chęć do dalszego działania i rozwijania własnej firmy! Dziś dowiesz się kim jest Piotr Bucki i w jaki sposób udało mu się osiągnąć taki sukces. Jak wyglądały początki jego biznesu? Jak spotkał wspólnika i jak wyglądało powstanie firmy? Do tego Piotr opowiada o tym z jakimi problemami i przeszkodami musiał sobie poradzić i jak przetrwali w pierwszym roku, a następnie zatrudnili pierwszych 100 pracowników. Ponadto:

Wartość zwykle płynie z książek, których autorzy doświadczali opisywanych przez siebie sytuacji lub wnikliwie badali je latami.Bywa tak, że we współczesnym, technologicznie rozwiniętym świecie, wartość płynie także innymi kanałami. Nie oznacza to, że aktualnie wydawane książki nie są wartościowe, a z pewnością nie wszystkie. Oznacza to jednak wielokanałową dystrybucję wiedzy i doświadczeń.Dziś dzielimy się doświadczeniami poprzez nośniki, które są optymalne dla większości zainteresowanych taką treścią. Mam tu na myśli blogi, głównie te eksperckie lub predestynujące do takich, ale także konferencje i wydarzenia tematyczne, szkolenia, kursy i oczywiście podcasty.Mój gość chętnie opowiada o swoich doświadczeniach związanych z rozwojem firmy J-Labs. Mogliście go już słyszeć w innych podcastach, w których występował w charakterze gościa, a także w jego autorskim podcaście Biznes w IT.Piotr Bucki, bo o nim mowa sam o sobie pisze: Zaczynałem karierę zawodową w 2000 roku jako programista – mam na koncie ponad milion linii kodu w Javie. Przepracowałem ponad 10 lat budując i rozwijając biznes. Jestem pomysłodawcą i współtwórcą j-labs, a od 2018 roku dzielę się wiedzą w podcaście Biznes w IT.Uderza mnie otwartość Piotra i jego skromność. Przy sukcesie, jaki odniósł pozostaje sobą. Jego pasje, którymi są praca i rower pozwalają mu funkcjonować zachowując nie work-life balance, a jak mówi Piotr life-life balace. Czyli nie równowaga w pracy i życiu, ale życiu jako kompletnej egzystencji - ciekawe podejście.Piotr także, jako kolejna osoba potwierdza moje założenia, że osoby z korzeniami w branży IT są bardzo poukładane, myślą i działają procesowo. Pracują w oparciu o prosty plan, często zapisany w formie czytelnego schematu.Przekonajcie się sami słuchając naszej rozmowy.Piotr poleca książki:David Heinemeier Hansson - Rework (eliminate, automate, delegate)Andrzej Jacek Blikle - Doktryna jakości. Rzecz o turkusowej samoorganizacjiMiłosz Brzeziński - książki i wywiadyFirma J-Labs:www.j-labs.plhttps://www.facebook.com/JlabsSoftwareSpecialists/Podcast: www.piotrbucki.plhttps://www.facebook.com/PiotrBuckiBizneswIT/ https://www.linkedin.com/company/biznes-w-it/#polskipodcast #rodk

Czy możliwa jest autonomia i/lub współdecydowanie w nie turkusowej firmie?TAK.Odcinek mówi o tym: * dlaczego autonomia/współdecydowanie jest ważna; * jak autonomie/współdecydowanie wprowadzić; * w jakich obszarach można to zrobić najłatwiej i efektywnie; * jak delegowanie koreluje z autonomią/współdecydowaniem;Wszystko na bazie doświadczeń z j-labs.Wiedza z odcinka jest nie tylko dla właścicieli, ale także dla managerów na dowolnym poziomie.Linki do miejsc wymienionych w odcinku: * J-LABS: http://www.j-labs.pl * IT Akademia J-LABS: http://itakademia.j-labs.pl * Odcinek o turkusie: http://bit.ly/2SfUjBd * Odcinek o delegowaniu: http://bit.ly/2SdeRu3Fanpage podcastu - like/follow aby wiedzieć więcej. * www.facebook.com/PiotrBuckiBizneswIT * www.linkedin.com/company/biznes-w-itSocial media - zapraszam do znajomych. * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-buckiStrona podcastu * www.piotrbucki.pl

Czy możliwa jest autonomia i/lub współdecydowanie w nie turkusowej firmie?TAK.Odcinek mówi o tym: * dlaczego autonomia/współdecydowanie jest ważna; * jak autonomie/współdecydowanie wprowadzić; * w jakich obszarach można to zrobić najłatwiej i efektywnie; * jak delegowanie koreluje z autonomią/współdecydowaniem;Wszystko na bazie doświadczeń z j-labs.Wiedza z odcinka jest nie tylko dla właścicieli, ale także dla managerów na dowolnym poziomie.Linki do miejsc wymienionych w odcinku: * J-LABS: http://www.j-labs.pl * IT Akademia J-LABS: http://itakademia.j-labs.pl * Odcinek o turkusie: http://bit.ly/2SfUjBd * Odcinek o delegowaniu: http://bit.ly/2SdeRu3Fanpage podcastu - like/follow aby wiedzieć więcej. * www.facebook.com/PiotrBuckiBizneswIT * www.linkedin.com/company/biznes-w-itSocial media - zapraszam do znajomych. * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-buckiStrona podcastu * www.piotrbucki.pl

Show Highlights  Terri talks about what the JP Morgan Life Sciences conference is all about, what she learned, who she met, and some of the trends and innovations in women’s health.   Terri talks about the importance of normalization language and conversations around women’s health and wellness, including sexual health and wellness.    Terri and Jacqueline talk about changing the norms around aging, especially around body image, and taking charge of our health in our midlife in setting ourselves best for life after 65.    Terri is excited about how digital health is being embraced within biotech and pharma in various areas including medication adherence, better patient targeting, better clinical trial design, and better leveraging of data to optimizing drug development and delivery.    They talk about data and data ownership being a big topic in 2019 and the ramifications of deals like 23andMe and GSK.    Terri and Jacqueline discuss the $8.1B invested in digital health in 2018, and what is included in digital health including the blurring of lines between health and wellness.        Terri’s Key Takeaway  We need to normalize the language and conversations around women’s health, wellness, and body parts.      References in the Podcast  TechCrunch article on CES / female sex-tech:  https://techcrunch.com/2019/01/08/ces-revokes-award-from-female-founded-sex-tech-company/?sr_share=facebook&utm_source=tcfbpage  More Men Named Michael Present at JP Morgan (2018):  https://www.statnews.com/2018/01/07/jpm-gender-diversity/  JP Morgan Life Sciences conference: https://www.jpmorgan.com/global/healthcareconference  Panty Prop: https://www.pantyprop.com/  RESI: http://www.resiconference.com/  Startup Health: https://startuphealthfestival2019.splashthat.com/  Healthcare Innovation Popup: https://medium.com/humble-ventures/teaming-up-with-mount-sinai-co-lab-for-open-innovation-in-healthcare-pop-up-ec3852b4bcb5  Humble Ventures: https://humble.vc/  Ogilvy: https://www.ogilvy.com/  Biotech Showcase: https://ebdgroup.knect365.com/biotech-showcase/  Springboard: https://sb.co/  True Wealth Ventures: https://truewealthvc.com/  Lisa Health: https://www.lisahealth.com/  Genneve: https://genneve.com/  Mighty Menopause:  https://www.mighty-menopause.com/  Madorra: http://www.madorra.com/  Pulse: https://lovemypulse.com/  B8ta: https://b8ta.com/  Astarte Medical:  http://www.astartemedical.com/  Watkins-Conti Products:  http://www.watkinscontiproducts.com/  Prima-Temp:  http://www.prima-temp.com/  Ceek Women’s Health:  https://ceekwomenshealth.com/  JLabs:  https://jlabs.jnjinnovation.com/  Saama:  https://www.saama.com/  Rock Health article on digital health: https://rockhealth.com/reports/2018-year-end-funding-report-is-digital-health-in-a-bubble/  Sandstone Diagnostics: https://trakfertility.com/  MyHealthTeams: https://www.myhealthteams.com/    Contact  You can follow Jacqueline Steenhuis on Twitter @TipsyCopilot or through her website https://www.jacquelinesteenhuis.com/.    You can follow Terri on Twitter at @terrihansonmead or go to her website at www.terrihansonmead.com.  Check out Terri’s new Medium publication:  https://medium.com/terri-hanson-mead  Feel free to email Terri at PilotingYourLife@gmail.com.  To continue the conversation, go to Twitter at @PilotingLife and use hashtag #PilotingYourLife. 

On this episode I speak with Kate Merton who is the head of JLABS at Johnson & Johnson.  JLABS helps entrepreneurs and technologists get their amazing ideas and products to patients and consumers that need them. Because of Johnson and Johnson, Kate and JLABS are able to assist innovators by providing space to work, receive mentorship and connection with investors.  Listen on to find out how Kate and JLABS help nurture entrepreneurs so they can make a positive impact in the world through healthcare.   ----------- Hey Offbeat Family, I really your listening to this episode. I would love to hear more from you and what you think of the podcast. Contact me: hello@theoffbeatlife.com

Melinda Richter, Global Head of Johnson & Johnson Innovation’s JLABs, enters the ICE House to explain how JNJ is empowering entrepreneurs to bring healthcare ideas from concept to consumer. Melinda shares her journey from growing up in Goodsoil, Saskatchewan to becoming a leader in the start-up culture of life science. Under her stewardship, JLABs has grown to 13 global locations and helped over 450 companies secure $11.6 Billion in financing, including 14 that have tapped the public markets.   Inside the ICE House: https://www.theice.com/podcast/inside-the-ice-house

Z tego odcinka dowiesz się jak skutecznie rekrutować specjalistów IT. Czyli programistów, testerów, ale też inne specjalizacje.Odcinek składa się z dwóch części. Pierwsza zawiera ogólne nakreślenie problemu oraz definicje skutecznego opisu stanowiska. Czyli jakie informacje musimy mieć jeszcze przed rozpoczęciem rekrutacji.Druga część zawiera informacje jak krok po kroku wygląda proces rekrutacyjny. Co w każdym kroku jest pożądanym/skutecznym działaniem, a co nie.Fanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

Z tego odcinka dowiesz się czego możesz spodziewać się po moich podcastach. Czyli: - kim jestem i gdzie mnie znaleźć - o czym będę mówić w moich podcastach - dlaczego tak, a nie inaczej kończę wszystkie podcasty Innymi słowy, jaką wiedzę możesz pozyskać od osoby, która od 10 lat prowadzi biznes w IT.Fanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

W tym odcinku poznasz moją drogę do 250 osobowej firmy. Czyli jak to zrobiłem, że po 8 latach pracy na etacie zacząłem budować firmę, która dziś - w 2018 roku - zatrudnia 250 osób w branży IT. „Złote myśli”, wplecione w historie to:* A nie każdy może…* Zmień myślenie a zmienisz całe życie* Co się musi stać aby…* Z kim przestajesz takim się stajesz* Szukaj pieniędzy nie pracy… myśl długo falowo* Wyjdź ze strefy komfortu… zainwestuj, zaryzykuj…* Rob to co nowe, inne, trudne albo czego nikt nie chce robić, a co Cie rozwinie* Decyzji warto pomóc* W biznesie najważniejsza jest sprzedaż* Liczy się dobrze przeliczony excel, czyli biznes plan* Iluminacja* MVP - Minimum Viable Product* Rozwijanie biznesu to żmudny proces* Ludzie, nie zasoby ludzkieLinki:malawielkafirma.plwww.sii.org.plwww.richdad.com (Robert Kiyosaki)ailleron.com (kiedyś SoftwareMind)j-labs.plFanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

Z tego odcinka dowiesz się jak skutecznie rekrutować specjalistów IT. Czyli programistów, testerów, ale też inne specjalizacje.Odcinek składa się z dwóch części. Pierwsza zawiera ogólne nakreślenie problemu oraz definicje skutecznego opisu stanowiska. Czyli jakie informacje musimy mieć jeszcze przed rozpoczęciem rekrutacji.Druga część zawiera informacje jak krok po kroku wygląda proces rekrutacyjny. Co w każdym kroku jest pożądanym/skutecznym działaniem, a co nie.Fanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

W tym odcinku poznasz moją drogę do 250 osobowej firmy. Czyli jak to zrobiłem, że po 8 latach pracy na etacie zacząłem budować firmę, która dziś - w 2018 roku - zatrudnia 250 osób w branży IT. „Złote myśli”, wplecione w historie to:* A nie każdy może…* Zmień myślenie a zmienisz całe życie* Co się musi stać aby…* Z kim przestajesz takim się stajesz* Szukaj pieniędzy nie pracy… myśl długo falowo* Wyjdź ze strefy komfortu… zainwestuj, zaryzykuj…* Rob to co nowe, inne, trudne albo czego nikt nie chce robić, a co Cie rozwinie* Decyzji warto pomóc* W biznesie najważniejsza jest sprzedaż* Liczy się dobrze przeliczony excel, czyli biznes plan* Iluminacja* MVP - Minimum Viable Product* Rozwijanie biznesu to żmudny proces* Ludzie, nie zasoby ludzkieLinki:malawielkafirma.plwww.sii.org.plwww.richdad.com (Robert Kiyosaki)ailleron.com (kiedyś SoftwareMind)j-labs.plFanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

Z tego odcinka dowiesz się czego możesz spodziewać się po moich podcastach. Czyli: - kim jestem i gdzie mnie znaleźć - o czym będę mówić w moich podcastach - dlaczego tak, a nie inaczej kończę wszystkie podcasty Innymi słowy, jaką wiedzę możesz pozyskać od osoby, która od 10 lat prowadzi biznes w IT.Fanpage podcastu * www.facebook.com/PiotrBuckiBizneswITKontakt z Piotr Bucki * www.facebook.com/piotr.bucki.1 * www.linkedin.com/in/piotr-bucki * www.piotrbucki.pl

Melinda Richter of JLABs never imagined she'd run a health sciences incubator. But a near-death experience inspired her to tap into a new purpose -- helping entrepreneurs in the health sciences. The shift would require her to rebuild her life and tap into every experience she'd been exposed to, from her tech background to her humble upbringing growing up with 8 brothers and sisters in rural Canada.

Ahead of Biotechnology Focus radio are some of the highlights of the week. ImmunoBiochem is haloed with angel investors after completing a new round of financing. Biotalent Canada provides subsidy to fund more “green jobs” for young graduates. eSight named one of the best inventions in 2017 by giving the gift of sight. Zymeworks presents results of ongoing completed dose escalation phase 1 oncology study. Welcome to another episode of Biotechnology Focus radio. I am your host, Michelle Currie, here to give you a run-down of the top stories of Canada’s biotech scene. +++++ Our first story this week takes us to the heart of Toronto with ImmunoBiochem Corporation as it completes a new round of financing led by angel investors and the company’s founding investor. The corporation has expanded its operations and is now located at Johnson & Johnson, JLABS, in the centre of Toronto. The company is focused on solving tumour heterogeneity by targeting a class of proteins in the tumour microenvironment with antibody drug conjugates (ADCs). This is an anticancer therapeutics class that combines the selectivity of targeted biologics with the potency of highly cytotoxic small-molecule drugs. One of the highest priorities of ImmunoBiochem is to transform the lives of patients who have triple-negative breast cancer – an extremely aggressive disease that has poor survival rates and does not respond well to major therapies. ImmunoBiochem in partnership with the Centre for the Commercialization of Antibodies and Biologics (CCAB) and the University of Toronto, has developed fully-human antibodies for the treatment of breast cancer and solid tumours. JLABS Toronto is a 40,000 square foot facility located in the MaRS Discovery District. The labs provide a flexible environment for start-up companies pursuing innovative technologies and research platforms for life sciences. Johnson & Johnson does not take an equity stake in the companies occupying their space or in developed products. ImmunoBiochem is a member of the Ontario Bioscience Innovation Organization and is partaking in the OBIO Capital Access Advisory Program. The company is also supported by MaRS Health and the Health Innovation Hub (H2i) accelerator at the University of Toronto. The company will be at the JPMorgan Healthcare week in California next month and is open to additional partnerships and investment. +++++   BioTalent Canada announces the extension of its wage-subsidy program aimed at helping new graduates across Canada gain access to “green jobs”. The federally funded program will provide $2.3 million in wage subsidies and create over 200 new placements over the next two years in biotech, environmental and likewise sectors. Career Focus Green Jobs is a wage subsidy initiate intended to alleviate youth unemployment. It has been funded in part by the Government of Canada’s Youth Employment Strategy. Wage subsidies have a positive record of jumpstarting careers, especially for biotech grads and aiding small to mid-sized enterprises acquire the funds to hire more talent. According to the BioTalent Canada’s 2017 labour market report on youth employment, almost 85 per cent of new graduates retain full-time employment after their wage subsidy ends. BioTalent Canada, a national non-profit HR association for Canada’s bio-economy, has a long track record of successful implementation of wage-subsidy programs and will disburse over $10.3 million in wage subsidies, to create 1,400 job placements over the next four years. The Green Jobs program will form an important component of those new placements. Eligible companies will be those with a sustainable development mission, or those with products or services that directly reduce carbon footprint, enhance recycling or reduce waste. Similarly, positions that are dedicated to those ends from other industries may also be eligible for the subsidy. Companies interested in applying are encouraged to visit biotalent.ca/wage-subsidies for more information. +++++   Time magazine has named eSight one of the best inventions in 2017. After years of challenging work, and millions of dollars, the company was able to develop electronic glasses that actually allowed the blind to see. Inspired by his two blind sisters, the founder had decided to use his engineering skills to find a solution they could live with. The organization believes that everyone deserves to see. This technology has the capability of changing millions of individual lives across the world. It will allow for mobility and freedom and for each person to experience those momentous moments when they can see their loved ones faces, their peers, and a whole new way to virtually see life. Dr. Brian Mech, president and CEO of eSight says that “For eSight to receive this recognition from Time is a wonderful affirmation of the breakthrough work we do on a daily basis to Make Blindness History. eSight’s world-class lab is the largest and most advanced, anywhere in the world, that specializes exclusively in developing clinically-validated medical devices that allow the legally blind to actually see and be independently mobile.” eSight will work on individuals with low vision, and who are legally blind. People who are legally blind have an acuity of 20/200 or poorer in their better eye. Low vision is another term often used, referring to people who have an acuity of 20/70 or poorer in their better eye. The eyes are very complex organs and there are many eye conditions that can cause blindness or low vision. There are many testimonials from legally blind individuals who have used this device can not express enough how much this technology has changed and enhanced their life. The company has seen tremendous amounts of interest from companies wishing to help their blind employees to schools wanting to give the gift of sight to students. Time magazine has aptly named eSight for being one of the best inventions in 2017. +++++   Lastly this week, Zymeworks Inc. presents the completed dose escalation portion of its phase I study of ZW25, a bispecific antibody targeting two distinct domains of the HER2 receptor. The HER2-mediated signaling pathway is perceived to contribute to tumour growth in several cancers. There have been 22 patients enrolled in the study – 11 with breast cancer, eight with gastric, gastroesophageal junction, or esophageal (GE), and three with other HER2-expressing cancers. Part one of the multi-part study was a standard dose escalation where patients received ZW25 either weekly or bi-weekly in cycles of four weeks each. The Study Highlights are: – Six Partial Responses (PR) were observed across all dosing groups. – Clinical benefit was observed in heavily pretreated HER2-high breast and GE cancer patients. – Breast cancer patients received a median of six prior HER2-targeted regimens for metastatic disease; partial response in 56 per cent (5/9) of breast cancer patients with measurable disease, with 89 per cent (8/9) experiencing a decrease in target lesions. – Three HER2-high GE cancer patients with measurable disease displayed shrinking tumours. – ZW25 was well-tolerated at all doses and schedules, with the most common adverse events being diarrhea, infusion reactions, or nausea. – The dose escalation portion of the phase I trial is complete and enrollment in the expansion cohorts is underway. There was a reduction in target lesions per RECIST criteria in 79 per cent of breast and GE cancer patients with measurable disease (11/14). The best overall response (BOR) in 17 patients that had at least one tumour restaging was six in breast and GE cancer patients’ PR (35 per cent), three with SD (18 per cent) and eight with progressive disease (47 per cent). Of the eleven breast cancer patients, all were HER2-high and had received a median of six prior HER2-targeted regimens for metastatic disease. Of the eight GE patients, six were evaluable for response, and had received a median of four prior systemic regimens. Three of five patients with measurable disease had a decrease in tumour size. +++++ Well that wraps up another episode of Biotechnology Radio. We hope you enjoyed it. If you have any feedback or story ideas, please reach out to us via press@promotivemedia.ca. From all of us here at Biotechnology Focus, have a wonderful week ahead. From my desk to yours – this is Michelle Currie.

An excellent podcast with the Global Head, Johnson & Johnson Innovation, JLABS, Melinda Richter.

Zaczynał na etacie w korporacji, potem był typowym mikro-przedsiębiorcą, aż stopniowo jego działalność zmieniła się w firmę, która dziś zatrudnia 200 osób i generuje przychody na poziomie 24 mln zł rocznie. Doszedł do tego w wieku 38 lat, realizując konsekwentnie prosty pomysł. Jak wygląda droga z etatu, przez własną działalność, aż do własnej mini-korporacji? Właśnie o tym rozmawiam dziś z Piotrem Buckim – współzałożycielem firmy J-Labs. Artykuł na blogu:

Zaczynał na etacie w korporacji, potem był typowym mikro-przedsiębiorcą, aż stopniowo jego działalność zmieniła się w firmę, która dziś zatrudnia 200 osób i generuje przychody na poziomie 24 mln zł rocznie. Doszedł do tego w wieku 38 lat, realizując konsekwentnie prosty pomysł. Jak wygląda droga z etatu, przez własną działalność, aż do własnej mini-korporacji? Właśnie […] The post FBO 044: Etat, własna działalność i wreszcie 24 mln zł przychodów. Jak to się robi? – Piotr Bucki z J-LABS appeared first on Marcin Iwuć – Finanse Bardzo Osobiste.

Zaczynał na etacie w korporacji, potem był typowym mikro-przedsiębiorcą, aż stopniowo jego działalność zmieniła się w firmę, która dziś zatrudnia 200 osób i generuje przychody na poziomie 24 mln zł rocznie. Doszedł do tego w wieku 38 lat, realizując konsekwentnie prosty pomysł. Jak wygląda droga z etatu, przez własną działalność, aż do własnej mini-korporacji? Właśnie o tym rozmawiam dziś z Piotrem Buckim – współzałożycielem firmy J-Labs. Czytaliście może [...] The post FBO 044: Etat, własna działalność i wreszcie 24 mln zł przychodów. Jak to się robi? – Piotr Bucki z J-LABS appeared first on Marcin Iwuć – Finanse Bardzo Osobiste.

Formerly of TSRI, Lynda is now part of a local start-up. Listen as we talk about industry pros and cons, endurance athletics and Richard Branson. Show notes: Abilita Bio company website http://www.abilitabio.com/ Biotechnology and networking resources SDBN – San Diego Biotechnology Network http://sdbn.org/   LSN – Life Science Network http://lifesciencenetwork.com/home   SDEE – San Diego Entrepreneurs Exchange http://www.sdentrepreneurs.org/   FBB – French Bio Beach http://frenchbiobeach.com/ WIB – Women In Bio http://www.womeninbio.org/   CLSA – California Life Science Association http://califesciences.org/   Two Scientists Walk into a Bar http://www.rhfleet.org/events/two-scientists-walk-bar   Suds and Science http://www.rhfleet.org/events/suds-science   Spotlight on JLABS http://jlabs.jnjinnovation.com/

In this episode, I interview Rebecca Yu, Head of JLABS Canada.  She was instrumental in setting up Johnson & Johnson Innovation’s first JLABS incubator outside the United States.  JLABS@ Toronto is a partnership with Johnson & Johnson Innovation, The University of Toronto, MaRS Discovery District, MaRS Innovation and the Government of Ontario in Canada.  In this interview, Rebecca talks about how she has overcome roadblocks throughout her career.  From a little girl who came to Canada without speaking a word of English, to become a clinical pharmacist, to be in the field of Government Affairs and to lead JLABS Canada.  It’s truly an honor to have Rebecca on the show.

Every company these days has a lofty goal.  App makers with silly camera filters say they exist to bring humans together. Every company says it is out to change the world and make it a better place, but often, that’s nonsense. Not so for today’s guest.  Professor Steve Henry is the founder and inventor of Kode technology who has worked to make commercialisation and mass application of research in partnership between his company and AUT. His work developed a compound which is now being developed into a potential cure for solid cancers. It’s also in development for products that could be used to prevent people with surgical implants getting infections. And he’s only just getting started with the applications of his technology.  He’s CEO of Kode Biotech- a biotechnology company he’s been building since 1996, taking his research into synthetic molecules and how applying them to cells and surfaces can change the way they interact with their environment. For example coating a cancer cell with a synthetic shape can make the body see it in a way that means it can fight it. Something Steve will explain better shortly. This idea, commercialisation, patenting and market development has seen Steve Henry selected as a finalist for the 2008 New Zealand Ernst and Young Entrepreneur of the Year and the 2011 recipient of the Royal Society of New Zealand's prestigious R.J. Scott medal, in 2015 Kode Biotech won the Supreme NZ Innovator Award and this year Steve has become the first Australasian to secure a spot in the world-leading Johnson and Johnson Innovation centre, JLABS, in Houston. To talk innovation, commercialisation and building biotech as a category, Professor Steve Henry joins us today. See acast.com/privacy for privacy and opt-out information.

This week we spoke to Josh Ghaim, CTO of Johnson & Johnson. We were interested in how at around 130 years old, one of the largest organisations on the planet can stay nimble, forward facing, and seek out innovation in new places. We met Josh at the Hello Tomorrow conference last year, and were interested in how important that kind of face time is with budding healthcare innovators. We were keen to break down the role of J&J Innovation, an arm of the company that seeks to develop healthcare through entrepreneurship. This includes the international JLabs and JLinx accelerators. Josh also spoke about their Africa Innovation Challenge, which offers budding founders up to $100,000, in the areas of early childhood development and maternal health to name a few.  

Coming up on this week’s show: Pfizer partners with a Canadian biotech on a new therapeutic antibody discovery project, Quark Ventures keeps rolling out the dollars and Bloom Burton & Co. to host its first award gala. We have all this and more on this week’s Biotechnology Focus Podcast. Welcome to another episode of Biotechnology Focus Podcast. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene. Story 1 Our first story this week takes us to TORONTO, ON- where Canadian healthcare investment banking firm Bloom Burton & Co., has announced that it will host its inaugural Award Gala at the Four Seasons Hotel in Toronto, ON on September 14, 2017. As part of this special event, the firm also plans to recognize Canada’s Healthcare Industry biggest star with its newly minted ‘Bloom Burton Award.’ According to the firm, it plans to bestow this award annually to an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who has made the greatest impact in Canada’s innovative healthcare industry. Bloom Burton & Co president Brian Bloom commented that it’s time to celebrate those who advance medical science, attract and provide risk capital, launch new products and companies on the world stage or announce significant monetization events, with The Bloom Burton Award celebrating today’s finest. Nominees will all healthcare subsectors including biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, healthcare services or healthcare IT sectors. The judges include respected international leaders in healthcare investment, entrepreneurship and journalism. Among them are Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.; Terrence Connolly, Executive Director, Global Alliances and Business Development, Celgene Corporation; Carl Gordon, Partner and Co-Head of Global Private Equity, OrbiMed Advisors; Andrew Hack, Chief Financial Officer, Editas Medicine; Oleg Nodelman, Founder and Managing Director, EcoR1 Capital; Melinda Richter, Head of Johnson & Johnson Innovation, JLABS; and Avik Roy, Opinion Editor, Forbes; President, The Foundation for Research and Equal Opportunity. narrowed list of three finalists will be announced at the Bloom Burton & Co. Healthcare Investor Conference, taking place May 1-2, 2017. For more information, visit www.bloomburton.com. Story 2 Vancouver-based ProNAi Therapeutics has changed its corporate name to Sierra Oncology. According to company president and CEO Dr. Nick Glover, the name change is about better reflecting the company’s oncology focus, specifically its pipeline of therapies that target the DNA Damage Response (DDR) network. The company believes there is a significant opportunity for therapeutics that target the DDR network to have broad potential in the treatment of cancer. Additionally, the company has successfully in licensed sponsorship of two ongoing Phase 1 clinical trials evaluating its Checkpoint kinase 1 (Chk1) inhibitor, SRA737, from the Cancer Research UK Centre for Drug Development, where it was discovered and initially developed. In accordance with the license agreement for SRA737, a $2.0 million fee is due to CRT Pioneer Fund LP for the achievement of this milestone. According to Glover, SRA737 targets Chk1, a key cell cycle checkpoint and central regulator of the DDR network. The company is concurrently also conducting preclinical research evaluating SRA737 in combination with other DDR agents including PARP inhibitors and Sierra Oncology’s proprietary Cdc7 inhibitor, SRA141, as well as with immuno-oncology therapeutics. Finally, as of January 10th, company shares started trading on the NASDAQ under the symbol ‘SRRA. Story 3 In Venture capital news, Canadian VC-firm Quark Venture Inc. along with its partner, Chinese investment bank GF Securities say they are investing US$25 million in Microbion Corp. through the firm’ss $656-million Global Health Sciences Venture Fund. Microbion, co-located in Vancouver, BC and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of antibiotic-resistant infections. Its lead compound, MBN-101, is the first in a new class of products to treat infections by attacking both bacteria and related microbial biofilms. Among other advancements, the investment will go towards enabling Microbion in the initiation and completion of a Phase 1B/2A study in diabetic foot ulcer infections, the study will evaluate both safety and efficacy endpoints including eradication of infections and of biofilms. In 2016, the U.S. Food and Drug Administration (FDA) granted MBN-101 Qualified Infectious Disease Product (QIDP) and Fast Track designations for adjunctive treatment of moderate and severe diabetic foot ulcer infections. According to Karim Lalji, chairman and CEO of Microbion Pharma Corp, and former Simon Fraser University graduate, that in addition to proceeding with the Phase 1B/2A study, the investment will also allow the company to continue a Phase 2a trial in orthopaedic infections as well as to advance its development of an inhaled formulation of MBN-101 to treat cystic fibrosis related infections. Story 4 Looking at our top R&D news story, Canadian and Australian prostate cancer researchers say they have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. Their findings, published online in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated cancers right from the get-go and therefore are resistant to therapy right up front, says co-principal investigator Dr. Robert Bristow, clinician-scientist at Princess Margaret Cancer Centre, University Health Network. He talks about the research in the following audio provided by UHN: Insert audio from video…. https://www.youtube.com/watch?v=dXlntpaWtaI In the published study, Dr. Bristow and co-principal investigators Dr. Paul Boutros at the Ontario Institute for Cancer Research, and prof. Gail Risbridger at Monash University, Melbourne, Australia, compared 15 patients with BRCA2-inherited prostate cancer with 500 prostate cancer patients from the general population with non-inherited (sporadic) prostate cancer. In the related study of 500 tumours from Canadian men with non-inherited prostate cancer also published in Nature, Drs. Bristow and Boutros analyses led to the discovery of a new genetic fingerprint that identifies when curable disease may turn aggressive. Although BRCA2-inherited disease affects less than two per cent of men with prostate cancer, Dr. Bristow says the research sets the stage to rethink ways to use other drugs differently to personalize treatment for more men. The next steps are to explore the use of novel therapies to offset the BRCA2-associated aggressiveness earlier on in the treatment of these men and improve survival in an otherwise lethal tumour, and he says this might include different types of chemotherapy or the use of molecular-targeted drugs that specifically target the changes associated with BRCA2 mutation. Funding for this reasearch was provided by the Movember Foundation through Prostate Cancer Canada, the Ontario Institute for Cancer Research, CPC-GENE, and The Princess Margaret Cancer Foundation. Story 5 Our final story this week sees drug giant Pfizer entering into a multi-year collaboration with Vancouver-based AbCellera Biologics, Inc. As part of the collaboration, the two sides hope to generate lead antibody candidates using AbCellera’s mAb discovery platform, specifically AbCellera plans to apply its proprietary monoclonal antibody (mAb) screening platform to attempt to discover function-modulating antibodies against undisclosed membrane protein targets. Carl Hansen, founding CEO of AbCellera commented that his company is increasingly being recognized as a leader in high-performance antibody discovery, and this deal validates this fact. He explains that what makes his company’s platform unique is that it is able to screen natural immune repertoires with unparalleled depth unlocking the most challenging discovery programs. Moroever he says this partnership not only reinforces his company’s business strategy but also brings an added benefit through the ability to work closely with the innovative team at Pfizer. Under the terms of the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer’s development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed. With that we’ve come to the end of another program. A big thanks to our technical director and production manager Laskey Hart and to the rest of the Biotechnology Focus research team. Be sure to check back next week to see all the latest news happening on the Canadian biotech scene. And if you like our show, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca .We’re also always looking for your feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus or by email Biotechnology_focus@promotive.net. For all of us here at Biotechnology Focus, thank you for listening.

Infectious disease physician, entrepreneur, and life-long innovator, Diego Miralles has pursued the frontiers of medicine on three continents, and in at least three distinct settings: academia, biotech startups, and the largest pharma company on earth, J&J. There, he founded both the J-Labs incubator and the J&J Innovation Network, which has offices around the world, including […]

On this week’s show, Biotechnology Focus senior writer Shawn Lawrence breaks down the April/May issue of Biotechnology Focus, the official opening of JLABS @ Toronto and much more!

Funds Four Singapore-based companies – real estate company CapitaLand, data centre provider DeClout, agribusiness Wilmar and logistics provider YCH Group – have been awarded S$40m ($29.2m) to back local startups. Johnson & Johnson expands JLabs to Canada. Invitalia boosts fund to $74.5m. US-based venture capital firm Geodesic Capital closed its inaugural fund at $335m with an … Continue reading "23 May 2016 – Johnson & Johnson, Invitalia, Geodesic Capital, Kaspersky, Slack Technologies, Intel and more"

By Alison van Diggelen, host of Fresh Dialogues   Judy Estrin is an influential tech entrepreneur, CEO of JLabs, and author of Closing the Innovation Gap. I caught up with her at SD Forum’s 12th annual Visionary Awards in Atherton, where she was one of four recipients. We talked about whether clean energy solutions can save the planet; […]

JLabs LLC CEO and author Judy Estrin puts the processes and philosophies of innovation under the microscope. Her current analysis indicates that we're short-changing the business arena and culture at large, as we've stopped planting the seeds for true, monumental invention and problem-solving.

Audio File:  Download MP3Transcript: An Interview with Judy Estrin President and CEO, Packet Design, LLC Date: September 13, 2007 NCWIT Interview with Judy Estrin BIO: Judy Estrin, CEO, JLABS, LLC. and author, Closing the Innovation Gap is a networking technology pioneer and Silicon Valley leader. Since 1981, she has co-founded eight technology companies and served as CTO of Cisco Systems. As CEO of JLABS, LLC, she is an advisor and speaker in the areas of entrepreneurship, leadership and innovation. In May 2000 she co-founded Packet Design, LLC, a network technology company. Prior to co-founding Packet Design, LLC, Estrin was Chief Technology Officer for Cisco Systems. Beginning in 1981 Estrin co-founded three other successful technology companies with Bill Carrico. Bridge Communications, founded in 1981, was a vendor of internetwork routers and bridges that went public in 1985 and merged with 3Com Corp. in 1987; Estrin served as Engineering Vice President and Executive Vice President of Bridge, and later ran the Bridge Communications Division at 3Com. Network Computing Devices, a maker of X terminals and PC-UNIX integration software, was founded in 1988 and went public in 1992; Estrin started with NCD as Executive Vice President and became CEO in 1993. Estrin served as CEO of Precept Software from the company's 1995 founding as a maker of streaming video software until Cisco Systems acquired Precept in 1998, and she became Cisco's Chief Technology Officer until April 2000. Estrin has been named three times to Fortune Magazine's list of the 50 most powerful women in American business. She sits on the boards of directors of The Walt Disney Company and The Federal Express Corporation as well as two private company boards -- Packet Design, Inc. and Arch Rock. She also sits on the advisory councils of Stanford's School of Engineering and Stanford's Bio-X initiative. She holds a B.S. degree in math and computer science from UCLA, and an M.S. in electrical engineering from Stanford University. Lucy Sanders: Hi, this is Lucy Sanders, the CEO of the National Center for Women and Information Technology, or NCWIT. Today we have another great interview with a fabulous woman entrepreneur. And with me is Larry Nelson from w3w3.com. Hi, Larry. Larry Nelson: Hello, I'm so excited to be here. Lucy: Why don't you tell us a little bit about w3w3.com, since the podcast series will be also syndicated on your site? Larry: Yes, and we've started already, and it's really popular so far. At w3w3.com, have it all set it where they can download it as a podcast, they can listen to it on their computer, and it's having great reception. Lucy: That's great! Also here is Lee Kennedy who is an NCWIT director and also, in an exciting new twist of events, is starting yet another new company called Tricallex. Welcome, Lee. Lee Kennedy: Thanks, I'm so glad to be here. Lucy: Well, and today we're interviewing somebody who is just somebody I'm thrilled to talk to because she loves data networking. Now you guys don't get on my case about this. I'm sure that she loves lots of other things, but I know she gets network congestion, and TCIP, and all those great packet protocols. Judy Estrin, welcome. Judy Estrin: It's nice to be here. Lucy: Judy is the co‑founder and chairman of Packets Design. And she sits on the board of the Walt Disney Company and also Federal Express. So, Judy, you know you certainly have done a lot in the area of networking, and not just networking but route analytics and all the different algorithms. Why don't you tell us a little bit about Packet Design first, and then we'll get into the interview? Judy: OK, Packet Design has actually evolved over the last five years. It started out in 2000 as a company that we started to target what we called medium term innovation. So we didn't want to just focus on one product area. We started a number of projects, and the idea was to either license technology or spin out companies. Now, we all know what happened in 2001 and 2002 in the networking market; actually and in the technology market, in general. So it was an interesting time to start a company like that. But we did spinout three companies: Verneer Network, Packet Design, Inc., and Precision IO. A couple of years ago, we changed the business model and stopped doing new projects and just focused our time on the spinouts that existed. So Packet Design, itself, is really somewhat of a shell company at this point. Packet Design, Inc., which I'm chairman of the board of (but not CEO), is in the route analytics business. Verneer is in the network security business. And Precision IO, unfortunately, ended up getting shut down because of, I would say, running out of patience in the eccentric community. Lucy: When you mention route analytics, tell us a little bit about what that entails. Judy: The products that Packet Design, Inc., which is really the spin off that most of the people from Packet Design, LLC went to, the products they provide, probably the easiest way to describe it, is allow you to get more information about an IP network, so that you can manage, diagnose, and plan more effectively. And it gives you information about the routing itself, which is why it is called route analytics, as well as the products that give you information about the traffic that goes on the network and correlates that traffic with the routing. And previously there'd not been products that understood the routing the way this product did. Lucy: Well, and that maybe gets us to our first question around technology because, certainly, I know enough about networking protocols to know that route analytics is an extremely difficult technology. How did you first get into technology? And as you look out into the future, what technologies do you think are going to be especially important? Judy: So, this is kind of a funny answer to have to how did I first get into technology, I would say I was born into it. And today it's common to have second‑generation computer scientists. But when I was growing up, it was not so common. But my father worked with Flid Noiman at the Institute for Advanced Studies, and they started the Computer Science Department at UCLA. My mother is also a Ph.D. in electrical engineering, and was one of the very early biomedical engineers. So I grew up in an environment filled with science and technology. I had a very strong aptitude toward math. And I used to joke that if computers hadn't been invented, I might have ended up being a statistician. So I'm very lucky that computers were invented. When I think of myself and what I really like to do, it's solving problems. And if you think of about technology and computer science, specifically, it really is about solving problems. And I, very early in my career, moved from being a dedicated engineer into management. And I was, in essence, an individual contributor for probably a couple of years before I started managing. And what I found is the same problem solving techniques that I learned in computer science worked very well in the world of solving overall problems, whether it was organizational or people or technological. So I was exposed to technology very early, and I loved it. When you ask me what technologies I think are cool today, as I look forward, some of the most interesting technologies I think are the ones that are, what I would call, interdisciplinary, essentially applying information technology to different things. So whether it's to the consumer market, when you look at entertainment or social networking or any of the other problems that technology is solving in that arena. The increase of mobility, so looking at the problems of trying to take everything we've done that runs so well on personal computers and make that information available on mobile devices. One of the areas that I'm very interested in, my sister happens to run this center at UCLA in this area, and I'm on a board of a startup, is something called sensor‑nets, which is the area of bringing the physical world, or being able to monitor the physical world, and bring information about the physical world into your information systems. Because you now can combine processors, sensors, and wireless together in a very small device that can be sprinkled around, and allow you to get information about the physical world that might be used for environmental needs, or energy, in data centers, in monitoring the elderly at home. There's a whole range of applications. So I think that is another interesting application. I think the application of information technology to healthcare and education will be very important areas, because both of those are areas we have big problems in. And I believe technology can really help solve them. And then last, it's a broad area, but anything having to do with what people call clean techs. So the whole area of energy efficiency as well as new forms of energy I think are going to be very interesting. And technology, information technology will play a role in solving those problems. Lee: Well, the area of sensors is also particularly interesting to me and us at NCWIT. Just a plug for a future NCWIT summit we're going to have at the University of Illinois, Urbana Champagne will be exactly, Judy, what you were just talking about. And we're talking about the future of computing and how it's driven from multiple disciplines. Judy: Great. Lucy: And Judy you may have already answered our next question when you talked about your love to solve problems. But the question is: why are you an entrepreneur? And what is it about it that makes you tick? Judy: You know it's interesting, a lot of entrepreneurs will tell you stories about how when they were kids they had a lemonade stand or they started a business, and I don't have any stories like that. When I was growing up, I don't think I ever imagined that I would become an entrepreneur. But when I graduated with my master's from Stanford, I had offers from a number of different technology companies. I was interviewing at Intel, at HP, Xerox, the classic large companies. But I also interviewed at a very small company with 50 people called XLog, which was a spinout of Intel. And I decided to go there, because a friend of my parents told me that the smartest people that he knew worked at that company. So I started off my career at a small company. And just became very passionate about what you could do in small groups. And how quickly we were able to move. And how innovative the environment was. And I realized, also, how much I enjoyed building my own culture, developing groups, developing an organization. So out of that XLog experience, I think, was probably what made me start to think that, you know, maybe I'd like to start something on my own. And the other thing is, because I went to a small company, I was able to move into management much more quickly than I think if I'd gone to a larger, more hierarchical company. And I found I loved managing and so the non‑technical side. I always stayed deep in the technology. But the business side of entrepreneurship, I've found that I really enjoyed. One benefit of being an entrepreneur: when you're building a company, you get a choice to stay involved in the technology and do the higher level executive functions. And you have a very broad scope. And I found that that was something that interested me. When you end up at a large company, you end up having to make a decision of either being at the top, and being very far away from the technology, or staying technical, and not being able to necessarily exercise the management side as much. So I think what about entrepreneurship makes me tick. It's a passion for an idea. Every company we started was because we were passionate about an idea and about solving a problem in the marketplace. Most of the companies were pretty ahead of their time. So we tended to look forward a lot in what we were doing. And I keep saying we. The companies that I was involved in, I co‑founded with my ex‑husband Bill Carrico. So that's the "we" that I'm saying there. Larry: Judy, you know I thought it's interesting that it was obvious since the very beginning of time for you, IT was going to be part of your life. But it wasn't until after you got your master's degree that you really started thinking about the possibility of being an entrepreneur. And by the way, this is Lucy's favorite question, having to do with: Who were the people in your life that shepherded you through this career path? And who were your mentors? Judy: Early on, as I was growing up, my parents were really my role models. And that is what led me toward science and to become a computer scientist. But both of them are academics. And so I was not at all exposed early on to the business world. And it really was at XLog that I first became exposed to the business world. And I would say my first mentor was Bill, my ex‑husband, because he came to XLog and was the one who promoted me into a management position. So I would say, if I had to pick an early mentor, it was Bill. But the reason I don't like the question is: I think as I have gone through my career, there are so many people that have influenced me. I watched everybody, whether it's people who have worked for me who have taught me things. I have people I have worked for. I sit on the boards of directors of some incredible companies with just terrific leaders. And watching them and how they lead influenced me. Watching people who I don't like the way they lead at times influences me, saying I don't want to be like that. So I would say that I really can't identify a small set, or a set of role models. I think I've pretty much built my career and have always taken a strategy of just learning from everyone around me. Again, from those people who have worked for me and those people I have worked for. Larry: I think you answered that question quite well. Lucy: Right. Judy: You know, I'm asked these days... People often ask will I mentor, get together and ask for help. And one of the things I like to tell people is that when you're looking around, and when you're looking to someone who has experience, and hearing about hearing about their experiences, don't listen to what they say and just say, "OK, I have to do it that way." What you need to do is listen to other people's experiences and then filter. And decide which of those things feel right for you. Because in the end, and I think this is probably the most important thing about mentoring and role models, one is most successful when you're being yourself and developing your own capabilities. That doesn't mean you don't learn along the way. But when you try to act like somebody else, and if it's not natural to your own personality and skills, it always backfires. Lucy: Well, and I think that's really well said as well. We certainly do learn from everybody around us. And I think you had a brilliant answer for that. The next question we have for you is maybe on the other end of your experiences, in terms of the tough times in your career and the challenges you've had. What was the toughest thing that you've had to face in your career so far? Judy: I'm going to say two things. They were kind of tied together. The Packet Design Model involved spinning out these companies, and then hiring executives to run them and getting back your investment for them. And it involved then me learning how to let go. Because if you spinout a company, the company has to become independent. The CEO of that company has to run the company. You can't have two CEOs. So one of the very interesting things for me was one: I learned how hard it is to find good executives, to find good leadership and that process of learning how to let go, which I think I have developed as a board member and is one of the things that makes me more effective as a board member today, is that I have learned when to suggest, when it's my business to poke in, and when not. And how to question in a way that helps the CEO think, and helps hold them accountable without meddling in their business or trying to do their job. So that's number one. But I would say, by far, the hardest thing that I had to do was being involved in the shutting down of Precision IO. It was the first time that one of the companies that I helped start had to outright fail. And we couldn't navigate an exit strategy for it. Every other time when there was something that didn't go exactly the way we wanted, we were able to navigate an exit. And whether it is acquisition or partnership or changing strategy, here, because of the timing, because of execution, leadership, the venture dynamic, we ended up just shutting it down. And having to let people go that I've been involved in hiring was just very tough for me. Lucy: It really is tough, I think, for anybody. And it's tough for the people on the receiving end. It's interesting how a lot of times; those are the changes in people's lives where they go off to do wonderful, exciting things. Judy: Right. And I'm happy to say that the core team that got let go, those that I have continued to touch base with, are all in great places. They were all terrific people and very employable. But it doesn't make it any easier to make that decision. Lucy: So, Judy, one of the reasons we are doing these interviews with women like you is we're hoping that a number of young people will listen to these, and learn, and get inspired to go off and, potentially, be entrepreneurs in their career. So if you were sitting there, what would be some of the best advice you would give them? Judy: Well, I guess a couple of things. One is: do it for passion, not for money. So it's wonderful to make money if you're successful. But if you're doing it for the money, and the money is what you're doing it for first, I guarantee you won't come up with as good an idea or be as successful. So every entrepreneur I've seen that is doing whatever they're doing (a new product, a new service), because they are passionate about solving a problem with a new type of technology, those are the ones that are most successful. I'm not going to say that having a company go public, or get bought, and making money from it is not great. And that has to also be a motivator, because the venture guys want you to want to make money, because they want to make money. But the passion has to be there. And that should be the number one. So I guess that's one piece. The second is: you have to be ready to fail. You have to be ready to fail, pick yourself up, and try again. I think that sometimes we get confused because it was such a long time of growth and opportunity in the IT business, that so many companies were so successful, that people forget how hard it is to really build a successful company. And more companies fail than succeed. And so you really have to be ready to fail. And everybody says it, but you have to be ready to do it and pick yourself up and try again. The third thing is: that when I think about what it takes to be an entrepreneur, I already talked about the passion. It takes flexibility and persistence. You really have to be willing to keep going and plow through obstacles. But you also have to have a sense of judgment and flexibility to know when that obstacle... Sometimes you need to push through the obstacle. Sometimes that obstacle is telling you something. And what it's telling you is: you need to be flexible enough to change your strategy a little bit. And so this balance between persistence that just has you pushing forward, ignoring the naysayers and just knowing that your vision is right, but the flexibility and the open mindedness, to be able to say to yourself, "You know what? Maybe it's not 100 percent right. And maybe I just learned something new that I have to change slightly or change dramatically." So that balance between persistence and flexibility. And then last, there are lots of people out of school that want to go right from school to being the CEO of a company. My advice is get experience first because it will make you a better entrepreneur. Again, I think everybody thinks it's easier to build a company that it really is. Now that experience might be at another entrepreneurial company where you go work somewhere and watch someone else do it. It doesn't have to be 10 years of experience but getting some experience first I think will make you a much better entrepreneur. I think the trend of get your degree and start a company is actually not a good one. Some people can do it but I think it's better to be able to watch others a little bit first. Lucy: I can really echo this notion of passion. Last night I listened to the three‑minute pitches of 10 young entrepreneurial teams here in Boulder. I got to be the judge. The ones that really were in love with their idea and passionate about it ‑ and you could really see that there was a subset that was and then a subset if I would have said, "Why don't you make black white?" they would have said OK. [laughs] Larry: Hmm. Lucy: So it was just kind of an interesting experience. You have given us a lot of, I think, great characteristics of entrepreneurs. I know that they are your personal characteristics as well in terms of flexibility and persistence and having good judgment. Do you have any other personal characteristics that you haven't shared with us so far that you think have given you an advantage as an entrepreneur? Judy: I work very hard. [laughs] So that's part of that persistence. I'm really willing to roll up my sleeves and work very hard. We have talked about passion. Communication skills ‑ I think that one thing that I have always been able to do is communicate my passion and my vision to a broad range of people, so whether it is to the customer, to the marketplace, to employees. It's not enough just to have the passion and vision. You have to be able to communicate it and get other people excited about it also, for instance, raising money. So, I think my communication skills probably have helped me. The other is that I tend to be very forward‑looking. I am always willing to question. I'm very open‑minded. So in terms of when you try to think about, "Well, how did you decide to start a company in this area?" that whole notion of being able to look at what is available and what isn't and how can you take technologies that exist and maybe do something different with them. So the whole arena of being able to question what is out there, question myself, be honest, and do kind of a self‑assessment about where I or the company is at any certain time, I think has helped. There are some entrepreneurs that go in one direction until they hit a wall. The ability to self assess and question oneself and what you're doing without becoming wishy‑washy, but just a healthy amount of it, I think is important. Then last I would say leadership. I love building teams of people and leading teams of people. I think the teams of people that have worked for me appreciate the relationship and the environment or the culture that we created. So I would say leadership is probably the last. Lucy: That's great. I sense you have learned a ton through all the startups you have built. Judy: I have. I would say leadership style is really what I am talking about. Lucy: So, one of the things about which we are always curious is, being an entrepreneur, especially with the phenomenally successful companies you have built or as an executive at Cisco, how have you brought balance into your personal and professional life. Judy: I would say that until I had my son, which was in 1990, in our second company, I didn't. All I did was work. I had no balance in my personal/professional life. The only reason it worked is Bill and I cofounded the companies together. So our personal and professional lives just melded into one. We didn't do anything except work. Having a child forced me to have balance because my son became my number one priority. It doesn't mean the companies weren't important. But there was no question in my mind about what my number one priority was. Then I had to begin to juggle. I think that what I always tell people is that you can do it but the first thing you have to realize this is really hard to acknowledge to yourself because you can't do everything. So you have to prioritize and figure out what you are not going to do. You know, I couldn't be at every event at his school. I could pick the ones I wanted to be at. I had to make trade‑offs and establish routines where I would leave work at 5:30 in order to be able to spend time with my son. But then I, at 8:30 or 9:00 would go back to email and work some more. So an analogy I like to give people is when you're juggling, good jugglers know how many balls they can juggle. They don't ever pick up any more than that. I think the mistake people make is at each stage of your life, if you have children at each stage of their lives, the number of balls you can juggle changes because the balls change in size. The different phases of the company take different amounts of attention. So in six month increments in my life, I have always said, "OK. How many balls can I be juggling?" because if you pick up one more than you know how to juggle, they all fall down. So you're much better off putting one down so that you can continue to juggle than having the whole thing fall apart. The other thing is learning to ask for help. That was very hard for me to learn how to do. Whether it's getting help in your personal life or getting help at work and delegating and getting other people to do things that maybe inside you know or think you could do better, usually it's just that you think you could do better and other people can do them just as well and you need to learn how to do it. Now that I am older and I'm in a different phase of my life, I try to more consciously balance personal and professional. I think for 25 years when I was running companies it was coping. Now I'm spending more time consciously saying I need to make sure that I pay attention to myself as well as others. Lucy: So, I think juggling is a wonderful way to describe it. It's a wonderful analogy. We have talked with a number of people who have also talked about integration and we have had other words. I think juggling is terrific. So you have really achieved a lot. There is a lot about your career at that we haven't even touched on in this interview. But we always like to ask our interviewees what's next for them. What is next for Judy Estrin? Judy: It's been an interesting couple of years in terms of changes in my life. For the first time I'm not running a company. A couple of years ago, I picked up my head and said, "What's next?" and decided that I wanted what's next to be something very different, that I do not want to start another company at this point in time. I do have my Board seats, which I spend a lot of time on and love. But I decided to write a book. I started about a year and a half ago and hope to have it in bookstores in the August timeframe, August '08. That is a very, very different type of endeavor than running a company. But the reason I did it was the same reason. It was passion for a topic. The book has to do with innovation. But it has not specifically targeted it as 'here is how to make your business more innovative', which is what most of the innovation books are about. It more looks at how you create cultures of innovation for science and technology and where we are as a country and the fact that we have lost some of the elements that made us so successful have eroded. So it's really a little bit of a broader perspective on not just businesses but the country and what we need to do to cultivate sustainable innovation looking forward. Lucy: Well, I've had the pleasure of seeing some of your early remarks that you gave a group a couple of months ago. I'm very much looking forward to the book because you have had very thoughtful ideas. So hurry up and finish it. Judy: I'm working as fast as I can. Larry: All right. Lucy: Really, thanks a lot, Judy for your time. I know you're really busy and we really appreciate you taking time out to talk to us. Larry: I want to thank you so much. You echoed one of my feelings that over the years we have learned more from our mistakes and failings than we have from our successes. Judy: No question. One of the big things in my book is that you need to failure as a step to success and not an end in itself. So if you're not willing to fail then you never try anything. Larry: That's right. Judy, I want to thank you for joining us today. By the way, you listeners out there, would you please pass this interview along to people that you know, that would be interested and maybe even should be interested. It's an excellent story. Just go to www.ncwit.org and that's where you can see all of the different interviews along with w3w3.com. Thank you much. Lucy: Thanks Judy. Judy: Bye‑bye. Series: Entrepreneurial HeroesInterviewee: Judy EstrinInterview Summary: For Judy Estrin, an interest in science and technology is in the blood: her older sister is an MD; her younger sister is a professor of computer science; and her parents both have PhDs in electrical engineering. Release Date: September 13, 2007Interview Subject: Judy EstrinInterviewer(s): Lucy Sanders, Larry Nelson, Lee KennedyDuration: 27:36